Shmuel Hess - 18 Mar 2026 Form 3 Insider Report for MediWound Ltd. (MDWD)

Role: COO & Chief Commercial Officer
Signature: /s/ Yaron Meyer, attorney-in-fact
Issuer symbol: MDWD
Transactions as of: 18 Mar 2026
Net transactions value: $0
Form type: 3
Filing time: 18 Mar 2026, 17:22:10 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Hess Shmuel	COO & Chief Commercial Officer	C/O MEDIWOUND LTD., 42 HAYARKON STREET, YAVNE, ISRAEL	/s/ Yaron Meyer, attorney-in-fact	18 Mar 2026	0002085305

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MDWD	Ordinary shares						4,085	18 Mar 2026	Direct	F1
holding	MDWD	Ordinary shares						3,000	18 Mar 2026	Direct	F2
holding	MDWD	Ordinary shares						3,800	18 Mar 2026	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	MDWD	Stock Option (right to buy ordinary shares)							18 Mar 2026	Ordinary shares	32,000	$8.13	Direct	F4
holding	MDWD	Stock Option (right to buy ordinary shares)							18 Mar 2026	Ordinary shares	32,681	$12.73	Direct	F5
holding	MDWD	Stock Option (right to buy ordinary shares)							18 Mar 2026	Ordinary shares	24,000	$18.54	Direct	F6
holding	MDWD	Stock Option (right to buy ordinary shares)							18 Mar 2026	Ordinary shares	31,000	$17.60	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F2	The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F3	The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F4	The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F5	The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F6	The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F7	The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.